TSE:4552
TSE:4552Pharmaceuticals

JCR Pharmaceuticals (TSE:4552) Q3 EPS Slide Challenges Bullish Profit Recovery Narrative

JCR Pharmaceuticals (TSE:4552) has reported Q3 2026 revenue of ¥8,991 million and basic EPS of ¥0.28, alongside net income excluding extra items of ¥34 million, setting a measured tone for the latest update. The company has seen quarterly revenue move between ¥8,512 million and ¥12,793 million over the past five reported periods, while basic EPS has ranged from a loss of ¥34.28 per share to a profit of ¥18.50 per share, giving investors a clear view of how earnings have been fluctuating...